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C-C motif chemokine ligand 20 regulates
neuroinflammation following spinal cord
injury via Th17 cell recruitment
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Abstract
Background: Spinal cord injury (SCI) is a severe traumatic injury that often leads to paralysis. The neuroinflammation
following SCI plays an important role during the secondary injury phase. C-C motif chemokine ligand 20 (CCL20) works
like a magnet to attract inflammatory cells and subsequently regulate inflammation. However, the role and
mechanisms of CCL20 in neuroinflammation following traumatic injury are poorly understood.
Methods: A modified Allen’s weight drop method was applied to induce a rat moderate contusion injury model. HE
staining was used to assess spinal cord histopathology, and the water content test was used to estimate spinal cord
edema. Motor function scores were quantified to evaluate locomotor ability, and leukocyte infiltration was observed
by CD45 immunofluorescence and flow cytometry. Additionally, qRT-PCR and ELISA were used to determine
inflammatory mediator gene expression. Th17 cell recruitment was identified by flow cytometry.
Results: Compared with the injury control groups, histological analysis of the lesion area and tissue edema revealed
reduced spinal cord edema and decreased lesion volume in the group administrated with CCL20 neutralizing antibody.
Locomotor activity, as assessed by Basso, Beattie, and Bresnahan (BBB) score, showed that CCL20 blockade was beneficial
for motor function recovery. Results also showed that leukocyte infiltration was reduced by neutralizing CCL20 at 7 days
post-injury. More importantly, expression levels of IL-1β, IL-6, and TNF-α at 24 h after SCI demonstrated that a reduced
inflammatory reaction in the CCL20 antibody group compared with the injury controls. Although CCL20 altered the
expression of IL-1β, IL-6, and TNF-α, it had no effect on anti-inflammatory IL-10 expression at 24 h after damage. Notably,
tissue flow cytometry confirmed that Th17 cell recruitment in the CCL20 antibody group was decreased compared with
the control groups at 14 days post-injury. Additionally, IL-17A expression, which is mainly secreted by Th17 cell, suggested
that CCL20 blockade also reduced IL-17A levels at 14 days after SCI.
Conclusions: These results suggested that CCL20 aggravates neuroinflammation following SCI via regulation of Th17 cell
recruitment and IL-17A level. Thus, CCL20-target therapy could be a promising clinical application for the treatment of
SCI.
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Background
Spinal cord injury (SCI) is often the result of a traffic acci-
dent, injury, or violence and has a devastating and complex
impact on the central nervous system. The prevalence of
SCI in the USA had reached 906 per million within the past
decade and continued to show a significant growth trend
[1]. By 2013, the National Spinal Cord Injury Statistical
Center (NSCIS) reported that approximately 273,000 pa-
tients suffered from SCI in the USA, with 12,000 new cases
in the USA annually [2]. SCI, which often leads to perman-
ent disabilities such as paralysis and loss of movement or
sensation, is characterized by primary injury from the phys-
ical trauma and secondary injury that may be amenable to
therapy. The secondary injury following SCI is mainly in-
duced by the activation of large numbers of cellular and
molecular changes, including spinal cord neuroinflamma-
tory reactions, vascular damage, neuronal and glial apop-
tosis, metabolic failure, and cellular excitotoxicity [3, 4].
Following disruption of the blood-spinal cord barrier, an
influx of inflammatory cells and a strong expression of in-
flammatory mediators induce a reactive process of sec-
ondary cell death in tissue surrounding the original
injury site [5, 6]. This inflammatory reaction continues
for days or weeks and could ultimately lead to cavita-
tion and formation of a glial scar, thereby exacerbating
neurological dysfunction.
Numerous studies have demonstrated the mechanisms
of neuroinflammation in SCI animal models and human
samples [4, 7–10]. Alleviation of the early inflammatory
response to SCI may limit the extent of tissue damage
and, accordingly, the subsequent disability [11, 12]. Des-
pite extensive experimental data suggesting that neuro-
inflammation is a pathogenic component of SCI, the
inflammatory reaction also appears to be vital for tissue
repair [13]. Recent studies have illustrated that the neu-
roinflammation following SCI exhibits neuroprotective
effects on neurons and glia, and this effect was beneficial
for tissue repair [14, 15]. It remains a challenge for re-
searchers to determine how to control crosstalk between
the nervous system and the immune system to ease neu-
rodegeneration while promoting axonal regeneration.
The exploration of therapeutic targets and suitable time
points during neuroinflammation has become a hot topic
in the SCI field.
A growing body of evidence in animal models has con-
firmed that T lymphocytes play an important role in spinal
cord injury. Gonzalez et al. showed that reduced T lympho-
cyte recruitment through the use of a chemoattractant
CXCL10 neutralizing antibody significantly enhances spinal
cord tissue preservation and functional outcomes [16]. CD4
+ T-helper (Th) cells are mediators involved in the response
to traumatic injury in the central nervous system (CNS).
Fee and his colleagues found that activated CD4+ Th cells
exacerbate acute traumatic brain injury in immunodeficient
mice [17]. As a subgroup of Th cells producing interleukin-
17 (IL)-17, Th17 cells play a role in inflammation and tissue
injury. Fossiez demonstrated that IL-17 mediates the re-
lease of IL-6 and IL-8, and these cytokines reflect the re-
sponse to inflammation and recruitment of neutrophils
into tissues [18]. Increasing evidence shows that Th17 cells
are involved in the inflammatory damage of nephritis, dry
eye disease, and acute viral myocarditis [19–21]. However,
the role that Th17 cells play in the pathogenesis of SCI re-
mains unknown.
Chemokines work like magnets to direct movements of
immune cells by binding to specific chemokine receptors
expressed at the cell surface. Subsequently, the attracted
immune cells arrive at their intended destination [22, 23].
C-C motif chemokine ligand 20 (CCL20), also known as
MIP-3α and LARC, is a small cytokine that is mainly re-
leased by neuron, astrocyte, and microglia in CNS. It is
noteworthy that CCL20 can attract not merely lympho-
cyte but also monocyte and dendritic cell. As the unique
receptor of CCL20, C-C chemokine receptor 6 (CCR6) is
preferentially expressed by Th17 cells [24, 25]. Addition-
ally, recent studies showed that CCL20/CCR6 interactions
direct Th17 cell migration, which ultimately leads to
progression of immune-mediated diseases [19–21, 26].
Several studies also suggested that CCL20 plays a pivotal
role in inflammatory cascades in brain injury and cerebral
ischemia [27–29].
In the present study, we hypothesized that CCL20 di-
rects Th17 cell migration to the injury site and alters
neuroinflammation within the SCI. We used in vivo
neutralization of CCL20 to demonstrate the functional
relevance of CCL20 in mediating the inflammatory re-
sponse after SCI. Finally, Th17 cell recruitment was eval-
uated to determine the mechanism of CCL20 in the
regulation of neuroinflammation following SCI.
Methods
Animals
Adult, male, Sprague-Dawley (SD) rats weighing 180 to
220 g were provided by the Experimental Animal Center
of Central South University (Changsha, China) and were
housed in individual cages in a climate-controlled room
with free access to water and food.
Animal model of contusion SCI
Anesthesia was induced with 4 % isoflurane and maintained
with 2 % isoflurane in 98 % O2. Throughout the procedure,
the depth of sedation was monitored by an absent response
to a toe pinch. A laminectomy was performed at the thor-
acic vertebra level 10 (T10) after shaving and cleaning in a
warm environment (Additional file 1: Figure S1). A moder-
ate contusion injury was induced using a modified Allen’s
weight drop apparatus (8 g weight at a vertical height of
40 mm, 8 g × 40 mm) on the spinal cord, as previously
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described [30]. Sham-operated animals were only subjected
to laminectomy. After surgery, the muscles were sutured in
layers and the skin incision was closed with 3-0 silk threads.
Penicillin G (40,000 U, i. m.) was administrated daily for
3 days to prevent infection. Abdominal massage was con-
ducted twice daily to help in the recovery of bladder func-
tion until full voluntary or autonomic voiding was obtained.
Rats that died for any reasons were excluded from the ex-
periment, and a new one was added to the study. The mor-
tality rate of this study was approximately 2 %.
Experimental groups and interventions
The rats were randomly assigned to four groups: sham-
operated rats (sham group), anti-CCL20 monoclonal neu-
tralizing antibody-treated SCI rats (CCL20 mAb group),
mouse immunoglobulin (Ig) G1 antibody-treated SCI rats
(isotype control group), and SCI rats that received no treat-
ment (SCI group). As previously described, the anti-rat
CCL20 antibody (MAB540; R&D Systems Inc., Minneapolis,
MN, USA) and mouse IgG1 isotype control antibody
(MAB002; R&D Systems) were dissolved in phosphate-
buffered saline (PBS) and diluted to 100 μg/ml [29]. CCL20
mAb group or isotype control group rats were administrated
an intraperitoneal injection of CCL20 antibody (100 μg/kg
body weight) or isotype control antibody (100 μg/kg body
weight) immediately after surgery, respectively.
Behavioral assessment
Three rats from each group were subjected to locomotor
activity evaluation at 1, 3, 7, 14, 21, and 28 days post-
injury using the Basso, Beattie, and Bresnahan (BBB)
score method. Two independent and well-trained testers
observed movement of each rat for 4 min and scored
motor functions according to BBB scales [31]. The final
score for each animal was obtained by averaging values
from both investigators. Rats with perineal infections,
limb wounds, or tail and foot grazing were eliminated
from the test.
Tissue preparation
For the quantitative real-time polymerase chain reaction
(qRT-PCR), enzyme-linked immunosorbent assay (ELISA),
and flow cytometry, rats were sacrificed by transcardiac
perfusion with cold PBS to eliminate RNA and protein
expressed by blood cells. The spinal cord was immediately
dissected on ice. Thereafter, 10-mm-long spinal cord seg-
ments containing the injury epicenter were removed as
quickly as possible. The samples, except for the flow cytom-
etry samples, were then flash-frozen and stored in liquid
nitrogen for subsequent RNA and protein extraction. Lym-
phocytes were isolated from the fresh spinal cord for flow
cytometry. For immunohistochemistry (IHC), immuno-
fluorescence (IF), and hematoxylin and eosin (H&E) stain-
ing, rats were sacrificed by transcardiac perfusion with PBS
followed by 4 % paraformaldehyde. The 10-mm-long in-
jured spinal cords were then carefully isolated and post-
fixed in 4 % paraformaldehyde for 24 h at 4 °C. Specimens
were then immersed in 15 and 30 % sucrose solution for
12 h, respectively. After fixation and dehydration, the spinal
cords were paraffin-embedded and processed into 6-μm
transverse sections. For the water content test, animals
were sacrificed without transcardiac perfusion, and 15-mm
spinal tissues were obtained at the edge of the injury site.
Spinal cord weight was subsequently measured using an
electronic analytical balance. Three rats from each group
were subjected to mouse IgG measurements from 0 h to
28 days post-injury by ELISA. Rat blood sample was drawn
from caudal vein and then centrifuged at 3000 rpm for the
collection of serum.
qRT-PCR analysis
The three spinal cords from each group at 1 and 14 days
after damage were used to measure mRNA levels. Total
RNA was obtained from 10-mm-long spinal cord samples
and extracted using TRIzol reagent (Invitrogen, Carlsbad,
CA, USA) according to manufacture instructions. Total
RNA from each specimen was reverse-transcribed to
cDNA employing the PrimeScript RT reagent kit with
gDNA Eraser (Takara, Tokyo, Japan), and qRT-PCR was
conducted using the SYBR Premix Ex Taq (Takara).
GAPDH expression was used as an internal control, and
expression levels of rat CCL20, IL-1β, IL-6, TNF-α, IL-10,
and IL-17A were expressed as fold increases or decreases
compared with the control. Gene expression analyses were
quantified using the 2−ΔΔCt method, in which mRNA
levels from the sham group were used as controls. Primer
sequences for qPCR were detailed in Additional file 2:
Table S1.
ELISA analysis
The three spinal cords of each group at 1 and 14 days post-
injury were used to detect cytokine protein levels by ELISA
according to manufacturer’s instructions (Cusabio Biotech
Co, Wuhan, China). Blood samples of each group from 0 h
to 28 days post-SCI were also used to measure mouse IgG
levels dynamically by ELISA according to manufacture in-
structions (Cusabio Biotech Co.). All assays were performed
in duplicates using recommended buffers, diluents, and
substrates. Immunoreactivity was determined by a micro-
plate reader at 450 nm (Multiskan FC Microplate Photom-
eter, Thermo Fisher Scientific Inc., Rockford, IL, USA). The
tissue cytokine concentrations were expressed as pg pro-
tein/ml while mouse IgG levels were expressed as ng pro-
tein/ml.
Spinal cord water content measurement
The three spinal cords of each group were used to meas-
ure spinal cord water content using the wet-dry weight
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method as previously reported to evaluate spinal cord
edema [32]. Briefly, rats were sacrificed at 72 h post-injury,
the time point at which peak spinal cord edema develops
after SCI according to a previous report [33]. The 15-mm
lesioned spinal tissue was immediately dissected and
weighed before and after drying in an electrothermostatic
blast oven at 95 °C for 48 h. The percentage of water con-
tent was calculated using the formula: [(wet weight − dry
weight) / wet weight] × 100 %. Spinal cord water content
was measured by investigators blinded to the experimental
groups.
Lesion volume quantification by H&E staining
After the final locomotor function test and BBB scoring,
which occurred 28 days after surgery, the spinal cord trans-
verse sections (6 μm thickness) from the width of the spinal
lesion site were stained with H&E. The sections were then
traced using the Image-Pro Plus software program (Media
Cybernetics, Rockvillie, MD, USA), and the lesion area and
spared tissue area were outlined and quantified. Spared
tissue was reported as the remaining areas where normal
spinal cord structure was preserved. Conversely, the le-
sioned tissue was defined as injury areas where normal
anatomical spinal cord structure was not preserved. The
section with the greatest percentage of lesioned tissue area
was assigned as the injury epicenter. Transverse sections,
with an interval of 400 or 1600 μm rostral and caudal to
the lesion epicenter, were analyzed for percentage tissue in-
jury and sparing.
Immunofluorescence staining
The three spinal cords from each group at 7 days after
injury were used to observe leukocyte infiltration. The sec-
tions were dewaxed and rehydrated, and antigens were
retrieved by heating in 10 mM citrate buffer (pH 6.0) for
10 min at 98 °C. The sections were then incubated with
10 % normal goat serum for 30 min at room temperature
to block nonspecific staining. Immediately after, the sec-
tions were incubated overnight at 4 °C with rabbit anti-
CD45 primary antibody (1:100, ab10558, Abcam, USA).
After three PBS wash steps, the sections were then incu-
bated for 1 h with a goat anti-rabbit fluorescein secondary
antibody (Alexa Fluor 488, 1:400, Jackson ImmunoRe-
search, West Grove, PA). Finally, the nuclei were counter-
stained with DAPI and observed as soon as possible.
Images were analyzed by Image-Pro Plus software to quan-
tify positive cells and total cells in five random fields of each
section. The semi-quantitative expression of CD45 was
assessed as percentage of positive cells per field = (positive
cells / total cells) × 100 %.
Immunohistochemistry staining
Transverse sections 3 mm rostral to the injury epicenter
were obtained from three rats of each group 1 and 14 days
post-injury. In brief, paraffin-embedded sections (6 μm
thickness) were deparaffinized with xylene and hydrated
through a graded alcohol step. Antigen retrieval was per-
formed by microwave irradiation in 10 mM citrate buffer
(pH 6.0) twice for 5 min at 800 W prior to cooling for
30 min. Subsequently, 3 % H202 was used to block en-
dogenous peroxidase activity for 15 min at room
temperature, and then sections were rinsed three times
for 5 min each with 0.01 M PBS. Afterwards, sections
were blocked with 10 % normal goat serum for 1 h to
reduce nonspecific staining and then incubated overnight
at 4 °C with primary antibodies: rabbit anti-macrophage
inflammatory protein 3 alpha polyclonal antibody (1:200,
ab9829, Abcam) and rabbit anti-IL-17A polyclonal anti-
body (1:100, orb48920, Biorbyt, UK). After PBS rinse
steps, the sections were incubated for 30 min at room
temperature with goat anti-rabbit secondary antibody
(1:800, ab6721, Abcam). Subsequently, immunoreactivity
was visualized by staining with diaminobenzidine (DAB)
for 3 min under a light microscope. Finally, sections were
counterstained with hematoxylin for 1 min and then ana-
lyzed using Image-Pro Plus software. The brown staining
indicated positive expression of the corresponding protein.
Percentage of positive cells was calculated identical to the
immunofluorescence protocol.
Flow cytometry
The nine rats from each group were subjected to quantifi-
cation of CD45-positive cell infiltration and Th17 cell
recruitment (three rats performed one test). Immediately
after removing the 10-mm-long spinal cord segment con-
taining the injury epicenter, the samples were placed in a
RPMI 1640 (Gibco) for single cell suspension preparation
as previously described [34]. Cell suspensions were pre-
pared by mechanical dissociation and were forced through
a 70-μm cell strainer (Falcon, USA). Afterwards, myelin
was removed following centrifugation on 37 % isotonic
Percoll (GE Healthcare Bio-Sciences AB, Uppsala, Sweden).
Isolated spinal cord lymphocytes were suspended in 1 ml
cell staining buffer and stained by trypan blue to count live
cell. The live cell frequencies of all samples were greater
than 95 %. Lymphocytes for CD45 flow cytometry were
stained with cell surface markers: anti-rat CD45 (0.125 μg,
PE, eBioscience, USA) or rat IgG1 K isotype control
(0.125 μg, PE, eBioscience). In addition, lymphocytes for
Th17 cell flow cytometry were then stimulated with a cell
stimulation cocktail (1:500, eBioscience, USA) in an incuba-
tor (37 °C, 5 % CO2) for 6 h. The cells were washed and
stained with cell surface markers: anti-rat CD3 (0.25 μg,
APC, eBioscience) and anti-rat CD8a (0.25 μg, FITC,
eBioscience). After that, the Fix/Perm buffer (eBioscience)
was used for fixation and permeabilization, followed by
intracellular staining with anti-rat IL-17A (0.125 μg, PE,
eBioscience) or rat IgG2a K isotype control (0.125 μg, PE,
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eBioscience). Finally, the lymphocytes were analyzed with a
Becton Dickinson FACSCalibur system using FlowJo soft-
ware (version 7.6; TreeStar, Inc., Ashland, OR, USA). Ini-
tially, CD3+ cells (T lymphocytes) were gated by vs. CD3
APC as the T-gate protocol. Additionally, owing to endo-
cytosis of CD4 molecules on the surface of T cells after IL-
17 stimulation, the CD3+ cells were analyzed for CD8 FITC
expression to counter-target the CD3+4+ (Th) cells. This
specific cell population was then evaluated for intracellular
IL-17A PE expression vs. CD3+8−. Thus, Th17 cells were
presented as CD3+CD8−IL-17A+ cells.
Statistical analysis
All data are based on at least three independent experi-
ments. The data are expressed as mean ± SD, except for
data from the behavioral assessment of BBB scores, which
is presented as mean ± SEM. Statistical analyses were per-
formed using SPSS 17.0 (SPSS Inc., Chicago, IL, USA).
Data from the BBB scores were analyzed using repeated
measures analysis of variance (ANOVA). For other data,
statistical comparisons were analyzed using t test or one-
way ANOVA followed by a Student-Newman-Keuls test.
A P value less than 0.05 was considered to be statistically
significant.
Results
Altered spatiotemporal level of CCL20 in the spinal cord
after SCI
We measured CCL20 expression levels in the spinal cord
at different time points from 0 h to 28 days post-injury
using qRT-PCR (Fig. 1a). CCL20 expression increased in
the SCI group and reached a peak level at 6 h after dam-
age, and then gradually declined to baseline at 7 days
post-injury. As shown in Fig. 1b, the mouse IgG level of
rat serum, as determined by ELISA from 0 h to 28 days
post-injury, significantly increased in the CCL20 mAb
group and isotype control group from 6 h to 28 days
post-SCI when compared with sham group and SCI
group. These data suggested that SCI leads to increased
CCL20 expression in the spinal cord, especially during
the early period of SCI. Additionally, CCL20 monoclonal
neutralizing antibody may persist for the entire period of
Fig. 1 Altered spatiotemporal level of CCL20 in the spinal cord after SCI. a The temporal profile (from 0 h to 28 days post-injury) of CCL20 mRNA
expression in the spinal cord, as determined by qRT-PCR, shows that SCI leads to increased CCL20 mRNA level in the spinal cord, especially during the early
period of SCI. b Mouse IgG levels of rat serum (from 0 h to 28 days post-injury), as determined by ELISA, are significantly increased in CCL20 mAb group
and isotype control group from 6 h to 28 days post-SCI. CCL20 immunostaining at 1 day post-injury in the sham group (c), SCI group (d), negative control
of the sham group (e), and negative control of the SCI group (f) indicates that CCL20 is mainly localized in the cytoplasm of gray matter neurons and glial
cells. The brown staining represents positive CCL20 expression. Black arrow indicates the CCL20 positive neuron and glial cell. Scale bar = 100 μm. +P< 0.05,
compared with the sham group; *P< 0.05, compared with CCL20 mAb group; &P< 0.05, compared with SCI group
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the observation even at the late time point (28 days)
where we evaluate neurological outcome and histopatho-
logical outcome of SCI.
Immunohistochemistry was applied to investigate spatial
expression of CCL20 in the spinal cord at 1 day post-injury.
Results showed that CCL20 was mainly localized in the
cytoplasm of gray matter neurons and glial cells, which was
in accordance with previous observations (Fig. 1c–f) [27].
By showing temporal and spatial CCL20 level in the spinal
cord with or without injury, these results demonstrated that
CCL20 is a promising target worthy of study.
CCL20 blockade improves neurological outcomes after SCI
The impacts of CCL20 on neurological outcomes of SCI
rats were assessed by the behavioral evaluation from
BBB scores and the severity of spinal cord edema from
water content test, which are closely related to clinical
disabilities. Following establishment of the contusion
SCI rat model, all animals were paralyzed in both hin-
dlimbs. We found spontaneous functional recovery after
SCI in all injury groups. As shown in Fig. 2a, there was
no difference in BBB scores between injury groups at 1
and 3 days post-injury, indicating that rats in different
groups had relatively comparable injuries. During the
observation period, as illustrated by increased BBB
scores, hindlimb locomotor activity gradually improved.
Compared with the SCI group or isotype control group,
motor function recovery significantly increased in the
CCL20 mAb group from 7 days post-injury, demonstrat-
ing that CCL20 blockade was beneficial for movement
recovery in SCI rats.
Spinal cord water content tests were performed to evalu-
ate edema severity at 72 h post-injury, the time period
when peak spinal cord edema develops after SCI. As shown
in Fig. 2b, water content of the SCI group and isotype con-
trol group significantly increased, whereas edema severity
was significantly reduced in the CCL20 mAb group (71.09
± 0.31 and 71.20 ± 0.57 %, respectively, vs. 67.44 ± 0.37 %).
These results demonstrated that neutralizing CCL20 re-
sulted in ameliorated spinal cord edema.
Taken together, these data showed that CCL20 blockade
improves motor function recovery and alleviates spinal
cord edema. CCL20 itself may exacerbate hindlimb motor
function deterioration and spinal cord edema in SCI rats.
Neutralizing CCL20 improves histopathological outcomes
in the injured spinal cord
H&E staining was applied to evaluate spinal cord lesion
size and tissue sparing following behavioral assessment
at 28 days post-injury. Varying sizes of the cystic cavity,
inflammatory cell infiltration, and the formation of a
glial scar around the cavity was observed in the injury
groups (Fig. 3a). We also determined the lesion area
and spared tissue area size of the injured spinal cord
using Image-Pro Plus software. Compared to the SCI
group or isotype control group, there was significantly
decreased lesion volume or increased spared tissue area
in the CCL20 mAb-treated rats at the injury epicenter
and in regions extending away from the epicenter in
both rostral and caudal directions (Fig. 3b, c). It is
worth noting that the results were consistent with BBB
scores at 28 days post-injury, illustrating that histo-
pathological outcome correlated with neurological
outcome.
CCL20 neutraliztion reduces leukocyte infiltration
As a marker of extravasated leukocyte, CD45, also
known as leukocyte common antigen, was used to evalu-
ate leukocyte infiltration and inflammatory response at
7 days post-injury [35]. Very little CD45 expression was
observed in the sham-operated rats. Sections from the
SCI group and isotype control group showed abundant
CD45 immunostaining, whereas the CD45-positive cell
infiltration was attenuated by CCL20 mAb (Fig. 4a). As
Fig. 2 CCL20 blockade improves neurological outcome after SCI. a Analysis of locomotor BBB scores after SCI (from 1 to 28 days post-injury). A
significant improvement in hindlimb motor function is observed in the CCL20 mAb group compared with the injury control groups from 7 days
post-injury. b The water content data shows that CCL20 blockade significantly alleviates spinal cord edema at 3 days post-SCI. +P < 0.05, com-
pared with the sham group; *P < 0.05, compared with the CCL20 mAb group; &P < 0.05, compared with the isotype control group
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shown in Fig. 4b, the percentage of CD45-positive cells
was 11.39 ± 1.49 % in the sham group, 27.83 ± 1.29 % in
the CCL20 mAb group, 42.27 ± 1.06 % in the isotype
control group, and 43.47 ± 1.02 % in the SCI group,
which demonstrated that CCL20 mAb administration
significantly reduced CD45+ cell accumulation. On the
other hand, we also detected CD45+ cell frequency by
flow cytometry. As shown in Fig. 5, compared with the
SCI group or isotype control group, anti-CCL20 anti-
body administration significantly decreased CD45+ cell
frequency at 7 days post-injury. These results indicated
that leukocyte infiltration, as well as neuroinflammation
during secondary injury, was significantly alleviated by
CCL20 blockade.
Neutralizing CCL20 attenuates local inflammatory
response and decreases expression of pro-inflammatory
cytokines
The local inflammation during secondary injury of SCI
was evaluated by expression of IL-1β, IL-6, TNF-α, and
IL-10 at 24 h post-injury. Expression of IL-1β, IL-6,
TNF-α, and IL-10 mRNA was quantified using qRT-
PCR. Compared with the SCI group or isotype control
group, treatment with neutralizing anti-CCL20 antibody
significantly decreased IL-1β, IL-6, and TNF-α expres-
sion at 24 h post-injury (Fig. 6a). Although, CCL20
altered the expression of pro-inflammatory cytokines, it
had no influence on expression of the anti-inflammatory
IL-10 at 24 h after damage. Expression of IL-1β, IL-6,
Fig. 3 Neutralizing CCL20 improves histopathological outcome in the injured spinal cord. a H&E staining of the spinal cord sections at 28 days
post-SCI shows varying sizes of the cystic cavity, inflammatory cell infiltration, and formation of a glial scar around the cavity. Scale bar = 1 mm. b, c
Quantitative data of lesion tissue and spared tissue shows a significantly decreased lesion volume and increased spared tissue area, respectively, in CCL20
mAb-treated rats at the injury epicenter and both rostral and caudal directions, respectively. +P< 0.05, compared with the sham group; *P< 0.05, compared
with the CCL20 mAb group; &P< 0.05, compared with the isotype control group
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TNF-α, and IL-10 protein was measured using ELISA.
Similarly, CCL20 neutralization significantly decreased
IL-1β, IL-6, and TNF-α expression compared with the
injury control groups at 24 h after SCI but had no sig-
nificant effect on IL-10 expression (Fig. 6b).
Overall, these results indicated that the neuroinflamma-
tory reaction of the CCL20 blockade group was milder
than the injury controls at 24 h post-injury. Although
CCL20 altered the expression of IL-1β, IL-6, and TNF-α,
it had no influence on the expression of the anti-
inflammatory IL-10 at 24 h post-injury.
Th17 cells are recruited by CCL20 after SCI
To determine the amount of Th17 cell accumulation in
the injured spinal cord, we measured IL-17A mRNA and
protein expression, which potentially represents the amount
of Th17 cells at 14 days post-injury. We analyzed IL-17A
expression at 14 days post-injury, because mRNA expression
of IL-17A culminated on day 14, as shown by qRT-PCR
(Additional file 3: Figure S2). As shown in Fig. 7a, SCI
induced a dramatic increase in IL-17A expression, whereas
this elevation was attenuated by CCL20 neutralization. Simi-
larly, IL-17A protein expression significantly increased in
the isotype control group and SCI group following contu-
sion injury, as measured by ELISA. However, treatment with
CCL20 neutralizing antibody significantly reduced IL-17A
protein expression (Fig. 7b).
Results showed that IL-17A was mainly localized in the
cytoplasm of the spinal cord lymphocytes and neurons
(Fig. 7c–f ). As shown in Fig. 7g, the percentage of IL-17A-
Fig. 4 CCL20 neutralization reduces leukocyte infiltration. a Immunostaining of the spinal cord sections at 7 days post-SCI shows various amounts
of CD45-positive cells in the different groups. CD45-positive cells are stained green, while the nuclei are stained blue. The immunostained areas in
the white box are magnified below. Scale bars are 50 and 100 μm, respectively. b The percentage of CD45-positive cells indicates that leukocyte
infiltration, as well as neuroinflammation during secondary injury, was significantly alleviated by neutralizing CCL20. +P < 0.05, compared with the
sham group; *P < 0.05, compared with the CCL20 mAb group
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positive cells was significantly reduced by CCL20 blockade
compared with the isotype control group and SCI group
(31.88 ± 1.31 vs. 44.77 ± 1.36 and 45.02 ± 0.99 %, respect-
ively). These results indicated that IL-17A expression was
significantly decreased by neutralizing CCL20. It could be
postulated that CCL20 might increase IL-17A expression
by recruitment of Th17 cells. Thus, lymphocytes were sep-
arated from the spinal cords of rats at 14 days post-injury
and analyzed by flow cytometry to illustrate the direct re-
lationship between CCL20 and Th17 cells.
We initially targeted CD3+ T cells from isolated lympho-
cytes (Fig. 8a). Subsequently, the isotype control-PE was
used for the isotype control in the IL-17A-PE staining
(Fig. 8b). In Fig. 8c, the CD8− IL-17A+ cells represented
the Th17 cells. As shown in Fig. 8d, the frequency of Th17
cell significantly increased in the isotype control group
Fig. 5 Neutralizing CCL20 reduces leukocyte infiltration. a Flow cytometry of the spinal cord at 7 days post-SCI shows the CD45+ cell of different
groups. b The frequency of CD45+ cell indicates that leukocyte infiltration was significantly alleviated by CCL20 neutralization. +P < 0.05, compared
with the sham group; *P < 0.05, compared with the CCL20 mAb group
Fig. 6 Neutralizing CCL20 decreases the expression of pro-inflammatory cytokines. a The qRT-PCR data at 24 h post-injury shows that treatment
with neutralizing anti-CCL20 antibody significantly decreased mRNA expression of IL-1β, IL-6, and TNF-α. However, CCL20 mAb had no effect on
the expression of the anti-inflammatory IL-10. b Similarly, ELISA data at 24 h post-injury illustrates that CCL20 blockade significantly reduced
protein expression of IL-1β, IL-6, and TNF-α but had no influence on the expression of IL-10. +P < 0.05, compared with the sham group; *P < 0.05,
compared with the CCL20 mAb group
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and SCI group compared with the sham group (2.96 ±
0.15 and 2.86 ± 0.12 %, respectively, vs. 0.06 ± 0.02 %).
However, the frequency of Th17 cell significantly de-
creased to 1.15 ± 0.12 % in the CCL20 mAb group, indi-
cating that CCL20 blockade directly reduced recruitment
of Th17 cells in the spinal cord.
Taken together, these data demonstrated that neutral-
izing CCL20 reduced Th17 cell infiltration and subse-
quent secretion of IL-17A. CCL20 itself may induce
recruitment of Th17 cells and subsequently expression
of IL-17A.
Discussion
SCI induces a series of robust immune responses via se-
cretion of cytokines and chemokines and a combined infil-
tration of peripheral leukocytes into the injured area.
Cytokines, chemokines, and leukocytes were the key
factors that observed in the present study to evaluate in-
flammatory responses following SCI. Neuroinflammation
during secondary injury may result in a further exacerba-
tion of neurological function outcome, because of the for-
mation of scar tissue and necrosis or apoptosis of neurons
and oligodendrocytes. Unlike other tissues, this may give
rise to permanent functional loss in the CNS, because of
the extremely limited ability to repair damaged axons and
replenish lost neurons [4]. Of note, Louveau and col-
leagues recently discovered functional lymphatic vessels
lining the dural sinuses, and these vessels carried both
fluid and immune cells from the cerebrospinal fluid [36].
The spinal cord may also has lymphatic vessels that trans-
port immune cells, which further supports the theory that
immune responses play a role in neuroinflammation fol-
lowing SCI. However, numerous studies over the past
decade have revealed that post-traumatic inflammation
can play a dual role. Neuroinflammation, except for the
deleterious effects, also exhibits a neuroprotective effect
on neurons and glia and is beneficial to the initiation of tis-
sue repair. Therefore, the time course after SCI becomes a
vital factor to manipulate pro- and anti-inflammatory re-
sponses to minimize tissue damage and to promote tissue
repair, respectively.
Initially, the inflammatory response post-SCI is domi-
nated by the recruitment of neutrophils that pass through
the broken blood-spinal cord barrier, this recruitment peaks
Fig. 7 CCL20 blockade attenuates the expression of IL-17A. a, b The qRT-PCR and ELISA data at 14 days post-injury show that mRNA and protein
expression of IL-17A, respectively, significantly decreased as a result of treatment with CCL20 mAb. IL-17A immunostaining at 14 days post-SCI in the
sham group (c), CCL20 mAb group (d), isotype control group (e), and SCI group (f) indicates that IL-17A was mainly localized in the cytoplasm of
lymphocytes and neurons. The brown staining represents the positive expression of IL-17A. Scale bar = 100 μm. g The percentage of IL-17A-positive
cells indicates that CCL20 neutralizing antibody significantly reduced the IL-17A secretion. +P < 0.05, compared with the sham group; *P < 0.05,
compared with the CCL20 mAb group
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at 1 day post-injury. Subsequently, blood-derived macro-
phages and activated CNS resident microglia dominate the
neuroinflammation from day 2 onwards. Shortly afterwards,
lymphocytes, although in small numbers, start to infiltrate
into the injured spinal cord. The major detrimental effect
of neuroinflammation after SCI is likely to occur within the
first 2 weeks [11, 37]. Thus, drug-targeted therapies to
regulate the inflammatory response following SCI would be
appropriate only for a limited period after injury. Therefore,
the present study investigated the possibilities of CCL20-
tageted intervention for the treatment of SCI only during
the acute period. Spinal cord decompression surgery and
drug therapies have limited benefits for SCI recovery. The
aim of the surgery is to create a comfortable environment
for self-healing of the injured spinal cord, but the self-repair
is very slow and uncontrollable. Methylprednisolone was
broadly accepted to treat SCI a decade ago. However, the
safety and efficacy of methylprednisolone has been more
recently criticized. Therefore, it is necessary to determine
neuroinflammatory therapeutic targets and corresponding
time points for alleviation of detrimental bystander effects
and facilitation of beneficial aspects.
CCL20 caught our attention, because its mRNA expres-
sion increased almost 37-fold at 6 h after SCI (Fig. 1a). In
the present study, we first investigated the impact of
CCL20 on neurological outcome after SCI. We found that
CCL20 blockade in the spinal cord is beneficial for im-
proving neurological function in SCI animals, as indicated
by ameliorated spinal cord edema, improved long-term
movement function, and decreased lesion volume (Figs. 2
and 3). These data are similar to studies focused on brain
injury [28, 29]. Because CCL20 expression increased in
Fig. 8 Th17 cells are recruited by CCL20 post-SCI. a Th17 cells from the spinal cord at 14 days post-injury were initially targeted by CD3+ T cells
from isolated lymphocytes. b The isotype control from the IL-17A-PE staining. c CD8− IL-17A+ cells represent Th17 cells. d The frequency of Th17
cell was significantly reduced by application of CCL20 mAb, indicating that CCL20 blockade directly decreases Th17 cell recruitment in the spinal
cord. +P < 0.05, compared with the sham group; *P < 0.05, compared with the CCL20 mAb group
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the spinal cord from 6 h to 7 days post-injury in the SCI
group (Fig. 1a), we hypothesized that CCL20 neutralization
is a protective response following SCI and that CCL20
could serve as a potential therapeutic target to improve re-
covery following SCI.
CCL20, as a chemokine, regulates inflammatory re-
sponses by recruiting Th17 cells, which has been previ-
ously shown in animal models of IgA nephropathy, dry
eye disease, and acute viral myocarditis [19–21]. There-
fore, we analyzed the role of CCL20 in spinal cord neu-
roinflammation after SCI. Results suggested that CCL20
blockade resulted in reduced leukocyte infiltration and
expression of pro-inflammatory cytokines (Figs. 4, 5, and
6), further indicating that neutralizing CCL20 alleviated
neuroinflammation following SCI. We also observed that
CCL20 had no effect on the expression of the anti-
inflammatory cytokine IL-10, indicating that CCL20 may
regulate neuroinflammation by directly manipulating IL-
1β, IL-6, and TNF-α expression, but not IL-10. These re-
sults have not been previously shown in other studies of
spinal cord injury or brain injury. Furthermore, we stud-
ied the mechanism of CCL20 during the inflammatory
response after SCI by measuring Th17 cells and expres-
sion of IL-17A. We found that CCL20 blockade results
in decreased recruitment of Th17 cells and subsequent
IL-17A expression in SCI rats (Figs. 7 and 8). Mean-
while, results from mouse IgG of rat serum reflected
that CCL20 mAb administrated in vivo may persist for
the entire period of the observation even at the late time
point (28 days) where we evaluate neurological outcome
Fig. 9 The postulated inflammatory positive feedback in neuroinflammation following SCI. IL-17 interacts with the corresponding receptors on
the surfaces of certain target cells and induces the production of IL-6, IL-1β, TNF-α, and CCL20. Subsequently, IL-6, IL-1β, and TNF-α further
stimulate IL-17 expression and differentiation of Th17 cells. The black solid line represents what we have proven in the present study. The purple
dotted line represents what we have speculated from other studies
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and histopathological outcome of SCI (Fig. 1b). In
addition, persistent neutralizing CCL20 after SCI may
gradually reduce leukocyte infiltration, pro-inflammatory
cytokine expression, and consequently neuroinflamma-
tion. The alleviation of neuroinflammation which plays
an important role in secondary injury mechanism may
finally influence the neurological and histopathological
outcomes in the later stage of SCI.
Based on numerous studies, Fossiez demonstrated that
IL-17 mediates the release of IL-6 and IL-8, and these
cytokines reflect inflammation and recruitment of neutro-
phils into tissues [18]. Miossec and Kolls concluded that
IL-17 also induces production of CCL20, IL-1β, and TNF-
α, which implicates IL-17 in the exacerbation of inflam-
matory responses [38]. Additionally, IL-1β and TNF-α is
thought to prompt Th17 cell development by enhancing
the effect of IL-17 on mRNA stability, leading to increased
levels of protein expression [39]. Bettelli indicated that IL-
6 is a key factor in initial differentiation of Th17 cells [40].
Therefore, together with results from Morishima [41], we
postulated that IL-17 interacts with corresponding recep-
tors on the surfaces of certain target cells and induce pro-
duction of IL-6, IL-1β, TNF-α, and CCL20. Subsequently,
IL-6, IL-1β, and TNF-α stimulate the expression of IL-17
and differentiation of Th17 cells, suggesting an inflamma-
tory positive feedback between Th17 cells and the induced
pro-inflammatory cytokines (Fig. 9). Thus, CCL20-based
therapy is an effective intervention to disrupt this inflam-
matory positive feedback from the initial source.
Results from the present study demonstrated that CCL20
regulates neuroinflammation following SCI via Th17 cells
recruitment and subsequent IL-17A expression. However,
further studies are needed to determine the remaining
mechanisms involved in the postulated inflammatory posi-
tive feedback. Although important discoveries were revealed
by the present study, there were also limitations. It should
be noted that this study examined only the impact of
CCL20 on Th17 cells and IL-17 expression but did not
address interactions between IL-17 and CCL20. We also
used CCL20 neutralizing antibody to block CCL20 rather
than stimulation of CCL20 bioactivity. These data may only
partially reflect the role and mechanism of CCL20 in neuro-
inflammation following SCI. We could not ascertain from
this data whether the observed alleviated neuroinflammation
was only due to reduced recruitment of Th17 cells or
whether other mechanisms were also at play. Moreover, it is
insufficient to investigate the role of CCL20 only by admin-
istration of CCL20 mAb immediately after SCI.
Taken together, results from the present study proved
the hypothesis that CCL20 directs Th17 cell migration to
the injury site and alters neuroinflammation after SCI.
This study expands on our previous understanding about
the functions and mechanisms of CCL20 in neuroinflam-
mation following CNS injury, suggesting that it could be a
potential therapeutic target for post-SCI interventions.
This research also opens a new avenue of therapeutic
strategies for SCI by manipulating immune responses.
Conclusions
SCI induces significant upregulation of CCL20, and neu-
tralizing CCL20 in vivo improves functional recovery, at-
tenuates tissue damage, and alleviates neuroinflammation
in a rat SCI model. Moreover, these results suggest that
CCL20 aggravates neuroinflammation following SCI via
regulation of Th17 cell recruitment and IL-17A expres-
sion. Thus, CCL20-target therapy could be a promising
clinical application for the treatment of SCI.
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